|Description||WZ-4002 is an EGFR phosphorylation inhibitor with selectivity for EGFR T790M. It has a framework of pyrimidine compound which is different from other EGFR inhibitors. WZ-4002 exhibits anti-tumor activity.|
|B0084-286777||50 mg||$198||In stock|
|Brife Description||EGFR phosphorylation inhibitor|
|Synonyms||WZ4002; N-(3-(5-chloro-2-(2-methoxy-4-(4-methylpiperazin-1-yl)phenylamino)pyrimidin-4-yloxy)phenyl)acrylamide; WZ 4002|
JNJ-26483327 is an orally bioavailable, small-molecule, multitargeted reversible tyrosine kinase inhibitor with potential antineoplastic activity. Multitargeted...
ZD-4190, a substituted 4-anilinoquinazoline, is a potent, orally available inhibitor of the vascular endothelial cell growth factor receptor 2 (VEGFR2) and of e...
EGF816 mesylate is the mesylate salt of EGF816 which is a covalent mutant-selective EGFR inhibitor and potently inhibits the T790M.
AG-879, a tyrphostin compound, is a dual EGFR/HER2 inhibitor that was administered together with androgen withdrawal therapy. It inhibits nerve growth factor (N...
A cell-permeable and highly selective EGFR tyrosine kinase inhibitor with IC50 value in the nanomolar range. Inhibition of EGFR induces apoptosis of tumor cells...
PF-06747775, a methylpurin derivative, has been found to be an epidermal growth factor receptor antagonist and could probably be effective against cell lung can...
CGP-59326, a pyrrolopyrimidine derivative, has been found to be an EGFR antagonist and could used in antineoplastic studies.
Tarloxotinib bromide, a pyridopyrimidine derivative, has been found to be a EGFR tyrosine kinase inhibitor precursor and could probably be effective in antineop...